Rationale: Atypical antipsychotic drugs (AAD) induce significant weight gain in female C57BL/6J mice. The effect of dietary fat on weight gain and serum lipids in this model is unknown. Objectives: Test the hypothesis that the obesigenic effects of these drugs are greater in the presence of a high-fat diet. Methods: Female C57BL/6J mice were treated with atypical antipsychotics for 3 weeks and fed either a low-fat or high-fat diet (4.6 vs 15.6% fat by wt). Food intake (FI), body weight (BW), body composition, and serum lipids were measured during treatment with optimized doses of olanzapine, quetiapine, and risperidone. Energy intake (EI) and feed efficiency (FE) were calculated. Group differences in change were analyzed via repeated measures analysis of variance (ANOVA). Serum lipid concentrations, EI and FE were compared using two-way ANOVA. Results: AAD-treated mice gained significantly more weight than controls after 3 weeks (Po0.001). Treatment and diet had significant effects on FI and EI over time (Po0.001). AAD-treated mice had significantly higher FE than controls (Po0.05); however, there was no significant drug by diet interaction (P ¼ 0.65). Risperidone low-fat mice gained significantly more absolute fat mass than placebo low-fat mice (Po0.05). All treatment groups, except quetiapine low-fat and olanzapine high-fat, gained significantly more absolute lean mass than placebo controls (Po0.05). Cholesterol levels were significantly lower in quetiapine and risperidone than placebo (Po0.05). Risperidone low-fat mice had significantly higher triglyceride levels than placebo and risperidone high-fat mice (Po0.05). Conclusions: A high-fat diet does not increase AAD-induced BW gain in female mice during a 3-week treatment period.
Introduction
Obesity, a common and serious 1, 2 health problem in the general population, appears to be even more common in the population of people with schizophrenia. 3 An important advance in the treatment of schizophrenia is the use of atypical antipsychotic drugs (AAD). AAD such as olanzapine, quetiapine, and risperidone are widely used as first-line pharmacotherapy for psychiatric disorders. 4, 5 Although AAD produce fewer side effects than earlier antipsychotics, they induce significantly more weight gain. 4, [6] [7] [8] [9] In the past decade, considerable evidence has emerged regarding the adverse metabolic consequences of AAD. [10] [11] [12] [13] Given that the estimated prevalence of obesity among patients with schizophrenia equals or exceeds that of the general population, this undesirable side effect is of even greater concern. 5 The extent of weight gain described with AAD may increase the risk for weight-related medical comorbidities 9, 14, 15 and this effect may also be detrimental to treatment compliance. [16] [17] [18] Epidemiologic studies have shown a standardized mortality ratio from cardiovascular disease for persons with schizophrenia compared to the general population. 19 Exacerbating any metabolic consequence through treatment can be devastating to this population which is already at increased risk for obesityrelated diseases.
A meta-analysis of 81 treatment trials that included data on weight change after 10 weeks of treatment 7 demonstrated a mean weight gain of 4.45 kg with clozapine, 4.15 kg with olanzapine, 2.92 kg with sertindole, 2.10 kg with risperidone, and 0.04 kg with ziprasidone. Results on quetiapine are controversial, but there has been at least some weight gain reported. Quetiapine-induced weight gain is usually reported as less than olanzapine and equivalent to risperidone; 20 others have shown minimal weight gain effect of quetiapine after 1 year of treatment. 21 In addition to increased weight gain, AAD influence serum lipid levels and there are some indications that AAD such as quetiapine, olanzapine, and clozapine are associated with higher risk of hyperlipidemia. 22 Quetiapine and clozapine primarily elevate serum triglyceride (TG) levels. 23, 24 Olanzapine is associated not only with severe cases of hypertriglyceridemia but also hypercholesterolemia with higher low-density lipoprotein (LDL)-c and lower high-density lipoprotein (HDL)-c levels in olanzapine cohorts. 25, 26 On the other hand, AAD such as risperidone, ziprasidone, and aripiprazole appear to be associated with lower risk of hyperlipidemia. [27] [28] [29] The effects of AAD on cholesterol and triglycerides in rodent models have not been well characterized.
Previous studies have shown that C57BL/6J mice develop obesity and diabetes when fed a high-fat diet. [30] [31] [32] Hence, we sought to investigate the effects of short exposure to high-fat diet in an AAD-induced weight gain model. 33 Our previously established paradigm showed significant weight gain following 3 weeks of treatment; however, the mice did not show significant fat mass increases over the 3 weeks. The present studies were designed to investigate the effects of high-fat diet within the current paradigm (3 weeks of treatment) to see if mice would gain fat. Introducing a weight-gain promoting factor such as a high-fat diet to our mouse model of AAD-induced weight gain could mimic the existing unhealthy environment that many persons with schizophrenia are exposed. Herein, we assessed the effect of a highand low-fat diet on the extent of AAD-induced weight gain using a defined mouse model.
Methods and procedures
Optimal dosing experiment To determine the dose of AAD that elicited the greatest weight gain, female C57BL/6J mice (12 weeks old) were given oral doses of olanzapine (3, 6, 12, 18 , and 24 mg/kg BW day), risperidone (0.125, 0.25, 0.5, 1, and 4 mg/kg BW day), or quetiapine (30, 45, 60, 75 , and 90 mg/kg BW day) for 4 weeks. Repeated measures analysis of variance (ANOVA) was used to determine if there were significant differences among dose within an AAD. The mice used for the optimal dosing experiment were not used in the low-and high-fat diet experiment.
Low-and high-fat diet experiment Female mice were weighed and had body composition assessed by dual-energy X-ray absorptiometry (DXA) at baseline (week 0) before administration of AAD treatments and before being given either a low-or high-fat diet. The time established for the experiment was 3 weeks because previous data showed maximum weight gain after 3 weeks of AAD treatment. After starting drug treatment and the two diets, body weight (BW) and food intake were assessed weekly over the 3-week experiment. During the 3 weeks of treatment, mice were given peanut butter pills as described previously 33 containing the appropriate amount of drug twice a day (0900 and 1500 hours). Final body composition was assessed at the end of week 3.
Animals for low-and high-fat diet experiment 
Dosing and drugs
Appropriate amounts of each drug were added to heated peanut butter, mixed, and made into 'pills' as previously described. 33 Peanut butter pills containing half the daily dose were given twice a day (0900 and 1500 hours) to achieve the complete daily dose. 
Treatment groups
Mice were randomly assigned to one of eight groups: placebo low fat (PL), placebo high fat (PH), olanzapine low fat (OL), olanzapine high fat (OH), risperidone low fat (RL), risperidone high fat (RH), quetiapine low fat (QL), or quetiapine high fat (QH). Sample size was 10 mice per group.
Body weight, food intake, energy intake (EI) and feed efficiency Body weights were measured at baseline (week 0) and weekly for 3 weeks. Food intake was measured weekly by subtracting the amount of food remaining at the end of each week from the amount of food in the hopper from the previous week.
Cages were checked and food spillage was minimal, any food found in the cage was weighed. Energy intake was calculated for each animal by multiplying the kcal/g of food consumed. The low-fat diet contained 3.9 kcal/g and the high-fat diet contained 4.41 kcal/g (data provided by the manufacturer). Feed efficiency was calculated by dividing the BW gained (mg) by the total energy consumed (kcal) during the 3 weeks of treatment.
Body composition
In vivo body composition (total body fat, soft-lean tissue, and bone mineral content and density) of mice was determined using a PIXImus densitometer (GE-Lunar PIXImus, Madison, WI, USA) as previously validated. 34 Mice were anesthetized using isoflurane and placed in a prostrate position on the imaging plate. All DXA measures were conducted between 1000 and 1300 hours. At 3 h prior to the DXA scan, food was weighed, recorded, and removed from home cage. This period of fasting helped to minimize any potential effect of gut fill on the DXA measures.
Serum lipids
Trunk blood was collected from each mouse following 3 weeks of treatment. Serum was isolated from each sample by centrifugation and the serum concentrations of total cholesterol and triglyceride were measured using the VITROS DT6011 System (Ortho-Clinical Diagnostics, Rochester, New York, NY, USA).
Statistical analyses
For each drug tested, repeated measures ANOVA was used to determine if there were significant differences in food and EI, BW, and body composition among groups over time. The interaction of diet and treatment was tested for each variable. Two-way ANOVA (diet and treatment as independent variables) was used to compare feed efficiency (FE) and cholesterol and triglyceride concentrations. Post hoc tests were performed on the least-square means to determine differences between groups. The criterion for statistical significance was Po0.05. All statistical analyses were performed using SAS (Version 8; SAS Institute Cary, NC, USA).
Results

Optimal dosing experiment
Weight gain was significantly greater in mice treated with olanzapine (6 and 12 mg/kg BW day) compared to control mice after 4 weeks of treatment (Po0.05); the other doses of olanzapine did not induce significant weight gain. Weight gain was significantly greater in risperidone-treated mice (0.125, 0.25, and 4 mg/kg BW day) compared to control mice after 4 weeks of treatment (Po0.01); the other doses of risperidone did not induce significant weight gain. After 4 weeks of treatment, weight gain was greater in quetiapinetreated mice (30 and 60 mg/kg BW day) compared to control mice (Po0.05); the other doses of quetiapine did not induce significant weight gain. Overall, the following doses resulted in the greatest weight gains: olanzapine (6 and 12 mg/kg BW day), risperidone (4 mg/kg BW day), and quetiapine (60 mg/kg BW day) and these gains were all significantly greater than placebo (Po0.05), Figure 1 . For olanzapine, the 6 and 12 mg/kg BW day-treated animals had similar weight gains; therefore, the optimal dose to be used in subsequent experiments was calculated to be 9 mg/kg BW day.
Body weight during the low-and high-fat diet experiment Baseline BWs were not significantly different among treatment groups; however, treatment had a significant effect on the change in BW over time (Po0.001). Dietary fat content did not have a significant effect on the change in BW over time (P ¼ 0.21), and there was no significant interaction between treatment and diet among the groups (P ¼ 0.88). Olanzapine-, risperidone-, and quetiapine-treated mice gained significantly more weight when compared to the corresponding (low-and high-fat diet) control groups after 3 weeks of treatment (Po0.05), Figure 2 .
Food intake during the low-and high-fat diet experiment ( Figure 3a ) Food intake changed significantly over time (Po0.001) and this was significantly affected by both treatment (Po0.001) and diet (Po0.001), and the interaction between treatment and diet over time approached significance (P ¼ 0.08). During all 3 weeks, there were significant effects of both AAD treatment (Po0.05) and diet (Po0.05) on FI, with
Effect of fat on BW gain MB Cope et al all AAD-treated groups eating significantly more than placebo-treated controls (Po0.01). Mice consuming the low-fat diet, regardless of treatment, ate significantly more food (g) over the 3 weeks of treatment compared to mice on high-fat diet (Po0.01).
Energy intake during the low-and high-fat diet experiment (Figure 3b ) Energy intake for all groups changed significantly over time (Po0.001) and this was significantly affected by both treatment (Po0.001) and diet (P ¼ 0.002). At week 1, there was a significant effect of AAD treatment on EI (Po0.001), no effect of diet on EI (P ¼ 0.265), and no significant interaction between diet and AAD treatment on EI (P ¼ 0.79). At week 2, AAD treatment significantly affected EI (P ¼ 0.037), diet had no effect (P ¼ 0.238), but there was a significant interaction between AAD treatment and diet on EI (P ¼ 0.038). Among the low-fat groups, AAD-treated mice had significantly greater EI than control mice (P40.05). In the high-fat groups, olanzapine-treated mice consumed more calories than control mice (P ¼ 0.025), and quetiapine-treated mice were borderline significant for consuming more calories than controls (P ¼ 0.06). At week 3, both AAD treatment (Po0.001) and diet (Po0.001) significantly affected EI; however, the interaction between AAD treatment and diet was no longer significant (P ¼ 0.561). Among low-fat groups, risperidone (RL)-and quetiapine (QL)-treated mice consumed significantly more calories than controls Effect of fat on BW gain MB Cope et al (Po0.05), and in the high-fat groups, all AAD-treated mice consumed significantly more calories than controls (Po0.01). With respect to diet, in general, the mice on highfat diet consumed significantly more calories over the 3 weeks compared to the mice on low-fat diet (Po0.001).
Feed efficiency during the low-and high-fat diet experiment (Figure 3c ) AAD treatment did significantly affect FE (Po0.001): all AAD-treated groups, regardless of diet, had significantly higher FE than controls. Dietary fat did not significantly influence FE (P ¼ 0.28) and there was no significant interaction between AAD treatment and diet (P ¼ 0.66). Among AAD treatments, regardless of diet, risperidone-treated mice had greater FE than olanzapine-treated mice (Po0.05), and there was a trend for risperidone-treated mice to have greater FE than quetiapine-treated mice (P ¼ 0.07).
Body composition during the low-and high-fat diet experiment Bone mineral content (Table 1) . At baseline, risperidonetreated mice had significantly higher bone mineral content (BMC) than control mice (P ¼ 0.02). None of the other AAD-treated mice were significantly different from controls at baseline. Bone mineral content increased significantly over time in all groups of mice (Po0.001). The change in BMC over time was significantly affected by treatment (Po0.01), but not diet (P40.05). At the end of the experiment, all AAD-treated mice had significantly greater BMC than controls (Po0.05). Olanzapine-treated mice had significantly more BMC gain than the corresponding controls, regardless of diet (Po0.05). Quetiapine-treated mice fed high-fat (QH) showed a significantly greater BMC gain than placebo (PH)-and risperidone (RH)-treated mice fed high-fat (Po0.01).
Bone mineral density. There was no significant effect of either treatment (P ¼ 0.09) or diet (P ¼ 0.19) on BMD at baseline; however, at the end of the experiment, diet had a borderline significant effect on BMD (P ¼ 0.053) with highfat groups having lower BMD while treatment was not significant (P ¼ 0.45). All mice had increased bone mineral density (BMD) over time (Po0.001), but this increase was not significantly affected by treatment (P ¼ 0.79) or diet (P ¼ 0.46).
Fat mass. Fat mass increased significantly over time (Po0.001) and tended to differ among groups after the 3 weeks of treatment (P ¼ 0.07), Figure 4a . Diet did not significantly affect the change in fat mass over time (P ¼ 0.23).
Lean mass. Lean mass was significantly affected by AAD treatment over time (Po0.001). All AAD-treated mice gained significantly more lean mass than control mice (Po0.05), Figure 4b . Risperidone-treated mice, regardless of diet, gained significantly more lean mass than olanzapine (Po0.01)-and quetiapine (Po0.001)-treated mice after 3 weeks of treatment. Diet did not have a significant effect on the change in lean mass (P ¼ 0.15).
Serum lipids during the low-and high-fat diet experiment AAD treatment had significant effects on serum cholesterol concentrations (Po0.01) with quetiapine-and risperidonetreated mice, regardless of diet, having significantly lower levels of total cholesterol than controls (Po0.05, Figure 5a ). Diet did not have a significant effect on serum total cholesterol (P ¼ 0.76). Serum triglyceride levels did not show any difference with respect to AAD treatment (P ¼ 0.48), but diet did affect triglycerides (Po0.05, Figure 5b ) with low-fat fed mice having higher triglycerides. RL mice had significantly higher triglycerides than PL and RH mice (Po0.05). Table 1 Change in body weight and body composition measures for female mice treated with AAD for 3 weeks (measurements were taken following a 3 h fast) 
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Discussion
This study is the first to demonstrate that dietary fat does not accelerate weight gain induced by chronic, oral AAD administration in female C57BL/6J mice. All AAD-treated mice had significantly higher BW gain, food intake, and EI compared to placebo-treated mice over the 3 week-experimental period, regardless of diet.
In a previous study, we demonstrated that AAD treatment induced increased weight gain in female mice. 33 In that study, mice given olanzapine showed the greatest weight gain, followed by animals given quetiapine and then risperidone. That order of weight gain was not seen in the current study, wherein, mice treated with risperidone gained the most weight: mice treated with quetiapine and olanzapine gained similar amounts. There are study differences which may explain this discrepancy: (1) in the current study, we optimized AAD dosage based on weight gain, leading to differences in doses between studies -the dose of olanzapine was reduced (12-9 mg/kg BW) and risperidone was increased (0.5-4 mg/kg BW, respectively) relative to our first study; (2) baseline BWs, even with identically aged mice, were lower in this study compared to the first study; and (3) the diets were different in this study compared to the first study. Our rational for optimizing doses based on weight gain was to maximize changes in body mass, thereby facilitating our ability to determine the cause of the weight gain. It should be noted that we have not attempted to give AAD to produce clinically relevant blood concentrations of the drugs, nor do we have data on blood concentrations from our current studies. Clinical studies have shown that olanzapine-induced weight gain among male schizophrenic adolescent inpatients treated for 4 weeks was owing to an increase in caloric intake with little change in resting energy expenditure or physical activity. 35, 36 Kalinichev et al. 37 reported that female rats treated for 14 days with olanzapine had significant weight Effect of fat on BW gain MB Cope et al gain, hyperphagia, increased body fat, and reduced lean tissue. Baptista et al. 38, 39 showed similar results for risperidone in female rats attributing the weight gain to increased energy consumption. Overall, appetite stimulation seems to be an important mechanism for BW gain induced by AAD. 40 In the current study, we found that food intake was increased by all AAD tested, suggesting that hyperphagia is indeed a cause of the increased weight gain. However, our analysis of FE (weight gain/kcal consumed) would suggest that hyperphagia is not the only mechanism responsible for the weight gain. Animals treated with AAD showed increased weight gain per unit of energy consumed implying that some aspect of energy expenditure was reduced. This reduction in energy expenditure could be in the form of a reduction in resting or basal metabolic rate, or in a reduction in activity-related energy expenditure.
Low resting metabolic rate (RMR) for a given body size and composition and low spontaneous physical activity are metabolic factors related to increased susceptibility to weight gain. 41, 42 It is well documented that increased weight gain in some obese mouse models is related to a reduction in RMR and core body temperature. 43, 44 Indeed, there have been several case reports of risperidone-and olanzapine-induced hypothermia in patients; [45] [46] [47] [48] [49] [50] however, these case studies do not indicate the risk of weight gain associated with the hypothermia. It is possible that AAD could lower RMR and increase the rate of weight gain among patients. One report described that schizophrenic patients treated with clozapine had lower RMR when measured using a ventilated hood system compared to calculations using standard prediction equations.
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Another potential mechanism for decreasing energy expenditure is through a reduction in physical activity levels. Female rats treated with low doses of olanzapine (1.2 mg/kg) had reduced motor activity during the dark phase and enhanced FE, 52 suggesting that these drugs may affect physical activity. Unfortunately, there are few reports describing the effects of AAD treatment on levels of physical activity in humans. In order to determine what comprises the weight gain induced by AAD, some investigators have used DXA to determine a pre-and post-treatment body composition. In human studies, the weight gain is mostly comprised of body fat. [53] [54] [55] Some reports have indicated that most of the weight gain in rodents is body fat, but these reports do not have pre-and post-treatment measures of body composition, only end point determination of body fat 37, 38, 56, 57 Ader et al.
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described weight gain in dogs administered olanzapine and risperidone and most of the weight gained was attributed to fat gain; however, total body composition was not assessed, only trunk. In total, these studies suggest the AAD-induced increase in BW is due in part to increased fat mass. For the most part, our results do not show a significant increase in fat mass with AAD treatment. Instead, the majority of weight gain in this study was due to increases in lean mass which we did not predict. One potential explanation is based on the age of the mice used in the current study. Studies have shown that overfeeding of young animals leads to an increase in lean tissue that accounts for approximately 80% of weight gain. 59, 60 In contrast, adult rats that are overfed show increases in lean tissue that comprise from 15 to 30% of the total weight gained. 61, 62 Thus, it may be of interest to test the effects of age on the accrual of fat and lean mass when weight gain is induced by AAD. Our model using young female C57BL6 mice (12 weeks old) has not shown fat mass gain on normal chow 33 or in the current experiment with a high-fat diet (15.6% of energy from fat). Coccurello et al. 63 have recently shown that young female CD-1 mice (10 weeks old) fed a high sucrose diet (10%) and treated with olanzapine (3 mg/kg) had significant weight gain and significantly heavier periuterine fat pads than placebo treated mice following 5 weeks of treatment. Our data do not include precise measures of individual fat pads, only changes in total lean mass and total fat over the 3 weeks of treatment. Perhaps, there is a reallocation of fat toward the visceral depots in young female C57BL6 mice treated with AADs that would not be detected with DXA measures. Future experiments (i.e. using microCT) will be needed to determine if young female C57BL6 mice reallocate fat stores to visceral depots. The current study showed that there were little or no interactions between diet and AAD with respect to weight gain. However, because of the short-term duration of our study, we cannot conclude that dietary fat would not modify weight gain in long-term experiments. Most diet-induced obese rodent models require the animals to have high-fat diets administered for several months to produce the obese phenotype. Currently, mice were only given high-fat diet for 3 weeks and did not start the diet until 13 weeks of age. Mice given low-fat diet ate significantly more food in order to achieve a similar EI as the mice fed high-fat diet. During week 3, mice fed high-fat diet showed a significantly higher EI than mice fed low-fat diet, but the experiment ended before a significant weight gain difference was achieved among mice fed the two diets. Future experiments with longer high-fat exposure will need to be performed to determine if high fat will eventually cause a greater weight gain.
There is evidence from a recent double-blind, activecontrol clinical trial that AAD may be differentially associated with changes in cholesterol and triglycerides. 64 Subjects receiving olanzapine and quetiapine showed increases, whereas those receiving risperidone showed decreases in cholesterol and triglycerides. Another study showed that first-episode schizophrenic patients treated with olanzapine for 12 weeks did not have significant increases in total cholesterol but did have significant increases in triglycerides. 54 Also, schizophrenic patients treated for 6 weeks with olanzapine had higher triglycerides and lower HDL than risperidone-treated patients. 65 In the current mouse study, AAD treatment did not have a Effect of fat on BW gain MB Cope et al significant effect on triglyceride concentrations. With respect to cholesterol concentrations, risperidone-and quetiapine-treated mice had significantly lower cholesterol compared to controls; olanzapine-treated mice did not differ from controls. It is unknown why cholesterol concentrations were not increased in olanzapine-and quetiapine-treated mice, but one might speculate that it is owing to species difference in the makeup of total cholesterol. 66 The findings from this study indicate that mice treated with AAD gain significant BW and that a high-fat diet does not induce a greater weight gain than a low-fat diet. Additional studies will be needed to determine if chronic high-fat feeding will enhance the effects of AAD-induced weight gain in this mouse model. Also, it will be important to monitor activity levels and energy expenditure in mice treated with AAD to determine if the cause of the weight gain is associated with not only an increase in EI but also a reduction in energy expended.
